{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:56:22Z","timestamp":1775091382858,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.rdc.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T18:50:40Z","timestamp":1587754240000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Future of Axial Spondyloathritis Treatment"],"prefix":"10.1016","volume":"46","author":[{"given":"Sinead","family":"Maguire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finbar","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2020.01.014_bib1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.014_bib2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019\u00a0Update of the American College of Rheumatology\/Spondylitis Research and Treatment Network Recommendations for the treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.014_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.014_bib4","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3 year results from the phase III trial; MEASURE 2","volume":"3","author":"Marxo-Ortega","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.014_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomised, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.014_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of Seckinumab 150\u00a0mg with and without loading regimen in ankylosing spondylitis: 104\u00a0week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.014_bib7","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long term efficacy and safety of secukinumab 150\u00a0mg in ankylosing spondylitis: 5 year results from the phase III MEASURE I extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.014_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4 years results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2020.01.014_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib10","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2020.01.014_bib11","first-page":"1","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"10.1016\/j.rdc.2020.01.014_bib12","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2020.01.014_bib13","unstructured":"A study of Ixekizumab (LY2439821) in Participants with Non-Radiographic Axial Spondyloarthritis (COAST-X) (2019). Available at: www.Clinicaltrials.Gov\/Ct2\/Show\/NCT02757352. Identification number NCT02757352. Accessed 31 Oct 2019."},{"issue":"24","key":"10.1016\/j.rdc.2020.01.014_bib14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL1RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2020.01.014_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/annrheumdis-2019-eular.6888","article-title":"Efficacy and safety of Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody in patients with axial spondyloarthritis: a 16-week results of a phase 3, multicentre, randomised, double blind, placebo-controlled study","volume":"78","author":"Wei","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib16","first-page":"27","article-title":"Primary efficacy of Netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2020.01.014_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/annrheumdis-2019-eular.6633","article-title":"OP0232 Netakimab reduces the disease activity of radiographic axial spondyloarthritis. Results of the ASTERA study","volume":"78","author":"Gaydukova","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/annrheumdis-2019-eular.6791","article-title":"FRI0391 Netakimab improves patient related outcomes in patients with radiological axial spondyloarthritis: results from randomised phase 3 trial (ASTERA)","volume":"78","author":"Gaydukova","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/annrheumdis-2019-eular.7123","article-title":"FRI0412 spinal and sacroiliac joints inflammation in patients with radiographic axial spondyloarthritis treated with Netakimab\u2013\u201316\u00a0weeks results of multicentre, randomised, double blinded, placebo controlled, phase III ASTERA study","volume":"78","author":"Smirnov","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2018-eular.7889","article-title":"Dual neutralisation of IL-17A and\u00a0IL-17F with Bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"77","author":"Van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/annrheumdis-2019-eular.6607","volume":"78","author":"Van der Heijde","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2019-eular.643","article-title":"Comparing composite measures of disease activity in psoriatic arthritis: results from a randomized phase 2 trial with guselkumab","volume":"78","author":"Helliwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib23","first-page":"1838","article-title":"Assessment of disease activity using RAPID3 and evaluation of treatment effect of Guselkumab in patients with PsA: results from a randomized placebo-controlled phase 2 clinical trial","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib24","unstructured":"Efficacy and safety study of SUNPG1622(2019). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02980705. Identification number NCT02980705. Accessed 31 Oct 2019."},{"issue":"10162","key":"10.1016\/j.rdc.2020.01.014_bib25","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2020.01.014_bib26","doi-asserted-by":"crossref","first-page":"2367e77","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2020.01.014_bib27","unstructured":"A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis (SELECT Axis 1) (2019). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03178487. Identification number NCT03178487. Accessed 31 Oct 2019."},{"key":"10.1016\/j.rdc.2020.01.014_bib28","doi-asserted-by":"crossref","first-page":"1108e10","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.014_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trial","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.014_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.014_bib31","series-title":"Study of apremilast to treat subjects with active ankylosing spondylitis (POSTURE)","author":"Celgene Corporation","year":"2000"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.014_bib32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.014_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2020.01.014_bib34","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:13Z","timestamp":1760181493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X20300144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0889857X20300144"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2020.01.014","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Axial Spondyloathritis Treatment","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}